Lateral Cord Magnetic Stimulation For Refractory Spastic Cerebral Palsy
Launched by SOCIEDAD ARGENTTINA DE NEUROMODULACIÓN · Sep 16, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called Lateral Cord Magnetic Stimulation (LCS) for individuals with spastic cerebral palsy, which is a condition that affects movement and can also lead to speech difficulties. The goal of the trial is to see if this non-invasive technique can help improve muscle control, movement abilities, and speech in patients who have ongoing challenges due to their condition. Researchers believe that LCS might be beneficial not just for spastic cerebral palsy, but potentially for other similar conditions in the future.
To participate in this trial, individuals must be at least 16 years old and have a stable form of spastic cerebral palsy that affects one side of the body more than the other. They should also have noticeable speech challenges and generally good mental health. Participants can expect to receive the magnetic stimulation treatment in a safe and controlled setting. It's important to note that there are some health conditions that would prevent someone from joining, such as serious heart or lung issues, or certain infections. Overall, this trial aims to explore a promising new approach to help improve quality of life for those with spasticity.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 16 years or older.
- • Spastic Cerebral Palsy with stable condition.
- • Motor disability unilateral or predominantly unilateral.
- • Clinically evident speech disorders.
- • Normal or slightly subnormal intellectual coefficient (I.Q 80 or more)
- • Absence of psychiatric disorders
- Exclusion Criteria:
- • Cardiac or severe respiratory disorders.
- • Steady abnormal postures (except possible orthopedic surgical correction)
- • Recurrent chronic bronchial or pulmonary infections.
- • Psychiatric disorders
- • Chronic recurrent urinary infections
- • Severe osteoporosis in affected limbs
- • Chronic skin ulcers
- • Drug addiction.
- • Episodes of Status Epileptucus
- • Personal history, or in close relatives, of medical legal complaint
About Sociedad Argenttina De Neuromodulación
The Sociedad Argentina de Neuromodulación is a leading clinical trial sponsor dedicated to advancing the field of neuromodulation through rigorous research and innovative therapeutic interventions. Committed to improving patient outcomes, the organization collaborates with medical professionals and researchers to conduct high-quality trials that explore new methodologies and technologies in neuromodulation. With a focus on ethical standards and scientific integrity, the Sociedad Argentina de Neuromodulación aims to enhance the understanding and application of neuromodulation techniques in clinical practice, ultimately contributing to the betterment of neurological health in Argentina and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hurlingham, Buenos Aires, Argentina
Patients applied
Trial Officials
Juan Carlos M Andreani, MD
Study Director
CENIT Foundation & Sociedad Argentina de Neuromodulación
Werner Braunsdorf, MD
Principal Investigator
Klinik von Magdeburg - Germany
Wojciech Maksymowicz, MD
Principal Investigator
University of Warmia and Mazury in Olsztyn- Poland
Tommaso Tufo, MD
Principal Investigator
Policlinico A. Gemelli University Hospital Foundation - Rome - Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials